Physician profile
Frederick Balch
NPI 1154735439
$818.56
in general payments reported to CMS, 2019-2025
15 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.10 · 2023: $128 · 2024: $193 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $110.88 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $106.89 | 2022-2024 | Mounjaro |
| Amgen INC. | $106.05 | 2024-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $95.54 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $87.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $59.61 | 2024-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $55.75 | 2025 | |
| Abbvie INC. | $46.74 | 2025 | |
| Exact Sciences Corporation | $39.55 | 2024-2025 | Cologuard Collection Kit |
| Neos Therapeutics, Lp | $20.88 | 2024 | Adzenys Xr-Odt |
| Aimmune Therapeutics, INC. | $20.84 | 2025 | Zenpep |
| Procept Biorobotics Corporation | $20.63 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.89 | 2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $15.14 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.73 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Balch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.